ArticleCell death & disease2026
C/EBP alpha agonist ICCB280 overcomes doxorubicin resistance in osteosarcoma through mitochondrial dynamics-dependent GREM1-MAPK activation.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The resistance of doxorubicin (DOX), the first-line chemotherapeutic drug for osteosarcoma (OS), stands as a pivotal obstacle in the effective treatment of OS. Alterations in mitochondrial dynamics and thereby affecting reactive oxygen species (ROS) accumulation play critical roles in DOX-induced cell death. However, the novel targets and pharmacological agents combating DOX resistance in OS via mitochondrial homeostasis and DOX-induced cell death manipulation is poorly understood. Herein, we showed that the C/EBPα/GREM1/p-ERK signaling pathway sensitizes OS to DOX by promoting mitochondrial fission and causing ROS-induced apoptosis. C/EBPα agonist ICCB280 and ERK pathway inhibitor PD98059 both played a DOX sensitivity augmentation role in OS in vitro and in vivo. The combined application of these two agents synergistically amplifies the cytotoxic impact of DOX, potentially overcoming DOX resistance and offering innovative therapeutic strategies for treating DOX-resistant OS. SCHEME： ICCB280 and PD98059 co‑administration counteracts doxorubicin resistance in osteosarcoma. When ICCB280 and PD98059 are co-administered, the activation of GREM1 by C/EBPα and the inhibition of ERK phosphorylation are intensified. This suppresses OPA1 expression, promotes mitochondrial fission, and effectively counteracts chemotherapy resistance in osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.